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MICROSCOPIC ALLIES: EXAMINING AND TACKLING
LEGAL AND REGULATORY BARRIERS TO THE
DEVELOPMENT OF PHAGE THERAPY
JACOB ZENT*
INTRODUCTION
In the course of discussing environmental law and policy, the re-
lationship between human beings and the microenvironment—the ever-
present microscopic realm encompassing the ecology and habitat conditions
of microbial organisms such as bacteria, protozoa, and viruses—is often
overlooked.1 Nonetheless, human activities have a definite and significant
impact on the microenvironment, which often leads to repercussions that
influence our health, economy, and quality of life.2 One way law and
policy impact the microenvironment is through the regulations placed on
medicine aimed at combating disease-causing or otherwise harmful micro-
organisms.3 Of particular note are our current policies regarding antibi-
otic medicine.
In the United States and wider Western world, traditional
penicillin-derived antibiotics have long been the medicine of choice when
dealing with bacterial infections and diseases.4 However, due to the overuse
and misuse of antibiotics, many disease-causing microbes are evolving
to resist antimicrobial medicines, posing a problem for the medical commu-
nity and society at large.5 One possible solution to this problem is the
development of phage therapy.6 A technique developed in the Soviet Union,
* JD Candidate, William & Mary Law School, 2018; BA English, Virginia Military Insti-
tute, 2015, summa cum laude. The author would like to thank the staff of the William &
Mary Environmental Law and Policy Review for their collective efforts on this Note. The
author also expresses sincere gratitude to his family, parents, and Professor Lederer for
their selfless support and encouragement.
1 See Charles Cockell, Environmental Ethics and Size, 13(1) ETHICS AND THE ENVIRON-
MENT 23 (2008).
2 Charles S. Cockell & Harriet L. Jones, Advancing the case for microbial conservation,
43(4) ORYX 520, 520–21 (2009).
3 See id. at 521.
4 Donna Duckworth & Paul Gulig, Bacteriophages: Potential treatment for bacterial infec-
tions, 16(1) BIODRUGS 57, 58 (2002).
5 C. Lee Ventola, The Antibiotic Resistance Crisis Part 1: Causes and Threats, 40(4)
PHARMACY & THERAPEUTICS 277, 277–78 (2015).
6 Duckworth & Gulig, supra note 4, at 57–58.
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phage therapy involves the use of bacteriophages—viruses which prey
exclusively on bacteria—to treat bacterial infections.7 This method of
treatment has many advantages: bacteriophages are plentiful and evolve
faster than the bacteria they prey upon, making any bacteria unlikely to
develop an immunity to such treatment, and produce few negative side
effects.8 However, with few exceptions, phage therapy is not approved for
use in humans in Western countries,9 and only three U.S. states currently
allow its limited use.10 Additionally, funding for phage therapy research
and clinical trials is insufficient and difficult to obtain since the patent-
ability of bacteriophage products—a complex and lengthy process to begin
with—has recently been called into question.11 Researchers have even com-
mented that the largest hurdle to developing phage therapy is regulatory.12
In this Note, I argue that the current regulatory scheme enforced
by the United States Food and Drug Administration (“FDA”) hinders the
useful research and development of bacteriophage medicine, a technology
that is sorely needed to better promote a healthy and sustainable micro-
environment. Thus, the pertinent FDA regulations must be amended in
order to accommodate and promote the greater exploitation of bacterio-
phage products for medical use in humans. In order to determine what such
an amendment might look like, I will examine the federal laws and FDA
policies that prove to be such a hurdle to the development of phage therapy.
I will also examine the policies of three U.S. states that allow the
use of phage therapy—Washington, Oregon, and Texas—to see what the
experiences of these states might teach. Furthermore, I argue that more
7 Id.
8 Sara Reardon, Phage therapy gets revitalized, 510 NATURE 15, 15–16 (June 5, 2014),
http://www.nature.com/news/phage-therapy-gets-revitalized-1.15348 [https://perma.cc
/LX5Z-RWYG].
9 Callum Cooper et al., Adapting Drug Approval Pathways for Bacteriophage-Based Thera-
peutics, 7(1209) FRONTIERS OF MICROBIOLOGY, at 1 (2016).
10 Doris Faltys, Evergreen Researcher Dr. Kutter Announces ‘There’s a Phage for That’,
THURSTON TALK (Aug. 3, 2013), http://www.thurstontalk.com/2013/08/04/evergreen-re
searcher-dr-kutter-announces-theres-a-phage-for-that/ [https://perma.cc/4HRH-LZRP]
(noting that Oregon and Washington allow naturopaths to use phage therapy); ANNA
KUCHMENT, THE FORGOTTEN CURE: THE PAST AND FUTURE OF PHAGE THERAPY 115–18
(2011) (noting Texas allows licensed physicians to use Phage Therapy).
11 Vincent Fischetti et al., Reinventing phage therapy: are the parts greater than the sum?,
24(12) NATURE BIOTECHNOLOGY 1508, 1509 (2006).
12 Isabelle Huys et al., Paving a regulatory pathway for phage therapy, EMBO REPORTS
(Oct. 18, 2013), https://www.researchgate.net/profile/Minne_Casteels/publication/258055
371_Paving_a_regulatory_pathway_for_phage_therapy_-_Europe_should_muster_the_re
sources_to_financially_technically_and_legally_support_the_introduction_of_phage_ther
apy/links/53faf1260cf20a454970296a.pdf [http://perma.cc/JK8N-5GSN].
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states should adopt policies promoting the medical use of bacteriophages.
This will increase awareness and acceptance of phage therapy, both among
the general public and the scientific community, and ultimately precipi-
tate its regulatory accommodation by the FDA—a necessary step toward
fully exploiting bacteriophage technology.
I also argue that the model for legalizing phage therapy used in
Texas is preferable to the model used in Washington and Oregon. This
is because the Washington and Oregon model places phage therapy—and
the onus for developing bacteriophage medicines—in the purview of “natu-
ropathic physicians,”13 who are ill-regarded by the medical establishment—
often thought to practice pseudoscience—and who are ill-equipped to
actually research and develop efficacious bacteriophage medicines.14 Not
only does this model stymie the development of efficacious bacteriophage
remedies, but it may also serve to associate phage therapy with pseudo-
scientific, naturopathic remedies in the eyes of many medical profession-
als, including researchers and physicians.15 Such discredit would hamper
any efforts to bring phage therapy into the discourse of the mainstream
medical establishment. Meanwhile, the preferable Texas model, which
allows licensed medical professionals to use bacteriophages as a supple-
ment to, but not in lieu of, established medical techniques, does not dis-
credit phage therapy by associating it with naturopathic pseudoscience;
instead, the model treats it as a legitimate medical technique.16 Further-
more, the Texas model places the onus for researching and developing
bacteriophage medicines in the hands of capable professionals, and fosters
a complementary relationship between phage therapy and conventional
antibiotic drugs that improves the efficacy of both treatment methods.17
Ultimately, it is my contention in this Note that, while the regula-
tion and maximum exploitation of bacteriophage medicine will require the
FDA to change its regulatory policy on bacteriophage medicine, state-level
legalization of the medical use of bacteriophage medicine has the poten-
tial to bring about greater cultural and scientific awareness and acceptance
of phage therapy, which could in turn induce the FDA to regulate phage
13 See Faltys, supra note 10.
14 See Julianna LeMieux, A Naturopath’s Human Experiment Ends In Death, AM. COUN-
CIL ON SCI. AND HEALTH (Mar. 23, 2017), https://www.acsh.org/news/2017/03/23/naturo
paths-human-experiment-ends-death-11039 [https://perma.cc/G9DG-FFTM].
15 See Faltys, supra note 10; see also Timothy Caulfield, Naturopaths and the creep of pseudo-
science, TORONTO STAR (Dec. 15, 2013), https://www.thestar.com/opinion/commentary/2013
/12/15/naturopaths_and_the_creep_of_pseudoscience.html [https://perma.cc/H4EB-KW4A].
16 22 TEX. ADMIN. CODE §§ 200.1–.3 (2003).
17 Id.
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therapy. Thus, in order to speed the regulatory acceptance of phage ther-
apy, more states should legalize the use of phage therapy within their
respective territories. However, states must take care when doing so, as
the details of how they legalize the use of phage therapy may prove laden
with consequential implications. For an example, I reference the differences
between the Texas and the Washington-Oregon models, and urge states to
draw inspiration from Texas rather than Washington and Oregon.
I. OVERVIEW
The bacteriophage was discovered in 1915 by British bacteriolo-
gist Frederick Twort, and independently reported in 1917 by French
microbiologist Félix d’Herelle, who commented that such viruses com-
monly appeared in the stool of dysentery patients soon before they began
to recover.18 George Eliava soon recognized the medical potential of bac-
teriophages, met with d’Herelle in Paris, and in 1923 founded the Eliava
Institute in Tbilisi, Georgia (then a part of the Soviet Union), dedicated
to the development of bacteriophage technology for medical use.19 Although
Eliava was executed as an Enemy of the Soviet People in 1937,20 the Soviet
Union nonetheless embraced his bacteriophage research.21 The institute
bearing his name continues his research into bacteriophage medicine,
uninterrupted even into the modern day.22
While the use of antibiotic medicines derived from penicillin flour-
ished in the Western world after the discovery of penicillin in 1928 by
Alexander Fleming,23 bacteriophage medicines enjoyed widespread use
behind the Iron Curtain.24 Soviet and other Eastern Bloc researchers put
great effort into developing bacteriophage cures for numerous bacterial
diseases.25 However, without the resources available to researchers in
Western Europe and the United States, Eastern Bloc research into bacterio-
phage medicine lagged behind the research and development of antibiotics
18 Leonard Norkin, Felix d’Herelle, the Discovery of Bacteriophages, and Phage Therapy,
VIROLOGY (May 20, 2015), https://norkinvirology.wordpress.com/2015/05/20/felix-dherelle
-the-discovery-of-bacteriophages-and-phage-therapy/ [https://perma.cc/UR2V-PUA5].
19 Id.
20 Id.
21 Reardon, supra note 8.
22 Id.
23 Rustam Aminov, A brief history of the antibiotic era: lessons learned and challenges for
the future, 1 FRONTIERS IN MICROBIOLOGY 134, 2 (2010).
24 Lawrence Osborne, A Stalinist Antibiotic Alternative, N.Y. TIMES (Feb. 6, 2000), http://
www.nytimes.com/2000/02/06/magazine/a-stalinist-antibiotic-alternative.html [https://
perma.cc/Y9W7-TV5Z].
25 Reardon, supra note 8.
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derived from penicillin, and did not proliferate to nearly the same extent
as penicillin-derived antibiotics.26
With the end of the Cold War, and the accession of several former
Warsaw Pact nations to the European Union, Eastern Bloc bacteriophage
research became available to Western European researchers.27 The Euro-
pean Union is already beginning to capitalize on this inheritance by estab-
lishing and financing the Phagoburn program, a clinical study dedicated
to developing and testing bacteriophage medicine for wound treatment.28
While such developments are encouraging, the main focus of this
Note will be on the United States and its relationship with phage therapy.
In recent years, the United States—as represented by both private corpora-
tions within the nation and relevant agencies within federal government—
increased its interest in bacteriophage technology.29 In 2006, the FDA and
the United States Department of Agriculture (“USDA”) approved the use
of bacteriophage products to prevent harmful bacteria from contaminat-
ing foodstuffs.30 However, the FDA has not yet approved the medical use
of bacteriophage products in humans.31
Meanwhile, at the state level, there has been movement toward
allowing the use of bacteriophage medicines.32 Notably, Washington’s and
Oregon’s laws allow for “naturopathic practitioners” to use any medical
technique which has gained legal acceptance somewhere in the world.33
Researchers interested in phage therapy have taken advantage of these
laws to develop and use bacteriophage medicines.34 One such researcher
26 See Osborne, supra note 24.
27 Reardon,supra note 8.
28 Id.; About Phagoburn, PHAGOBURN, http://www.phagoburn.eu/about-phagoburn.html
[https://perma.cc/XJR6-66UG] (last visited Jan. 21, 2018).
29 Positive Developments from Clinical Studies and FDA Approvals Pushing Biotech Stocks
to New Highs, PR NEWSWIRE (Oct. 18, 2017), https://www.prnewswire.com/news-releases
/positive-developments-from-clinical-studies-and-fda-approvals-pushing-biotech-stocks-to
-new-highs-651428793.html [https://perma.cc/98ED-GTAA] (noting AmpliPhi Biosciences
Corporation’s publication of preclinical data entitled “Activity of Bacteriophages in Removing
Biofilms of Pseudomonas Aeruginosa Isolated From Chronic Rhinosinustis Patients”).
30 Zach Mallove, Phages: A New Means of Food Safety?, FOOD SAFETY NEWS (May 21,
2010), http://www.foodsafetynews.com/2010/05/phages-a-new-means-of-food-safety/#.WK
5BPfnytPY [https://perma.cc/SC3M-5GMR]; EBI Food Safety, FDA Extends GRAS Approval
LISTEX(TM) to all Food Products, PR NEWSWIRE (July3, 2007), http://en.prnasia.com/re
leases/global/FDA_Extends_GRAS_Approval_LISTEX_TM_to_All_Food_Products-3917
.shtml [https://perma.cc/V7HY-WADU].
31 Cooper et al., supra note 9, at 1.
32 Faltys, supra note 10.
33 Id.
34 Id.
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is Dr. Elizabeth Kutter, who runs the Evergreen Phage Lab in Olympia,
Washington, and whose experimental use of phage therapy has found
some success.35 Texas law, meanwhile, allows licensed medical practitio-
ners a “reasonable and responsible degree of latitude” to offer their patients
“complementary and alternative medicine[,]” as long as there is scientific
evidence that such treatment will yield a reasonable potential for thera-
peutic gain.36 This provision has been interpreted to give licensed physi-
cians the ability to use bacteriophage medicines as a supplement to, but
not in lieu of, conventional medicines and remedies.37 As in Washington
and Oregon, this allowed researchers and physicians to develop and utilize
bacteriophage medicines.38 Two such individuals are Dr. Ryland Young,
head of the Center for Phage Technology at Texas A&M University, and
Dr. Randall Wolcott, whose wound treatment center in Lubbock, Texas has
been using bacteriophage medicines to treat patients’ wounds since 2007.39
II. BENEFITS OF PHAGE THERAPY
In discussing the advantages of using bacteriophage medicines over
the exclusive use of conventional antibiotic medicines, we cannot avoid
discussing the drawbacks associated with these established medical tech-
niques. Conventional antibiotic medicines revolutionized the relationship
between humans and the microenvironment, especially with regard to
disease-causing bacteria.40 However, the overuse and misuse of tradi-
tional antibiotics led to the evolution of strains of drug-resistant bacteria.41
One prominent example of this is Methicillin-resistant Staphylococcus
aureus (“MRSA”).42 These virulent strains of the S. aureus bacteria—
which is known to cause a diverse number of debilitating, disfiguring,
and even fatal ailments43—have, through natural selection, evolved a
35 Id.
36 22 TEX. ADMIN. CODE §§ 200.1–200.3 (2003).
37 KUCHMENT, supra note 10, at 115–18.
38 Id.; Faltys, supra note 10.
39 Azeen Ghorayshi, Mail-Order Viruses Are The New Antibiotics, BUZZFEED NEWS (Feb. 2,
2015), https://www.buzzfeed.com/azeenghorayshi/mail-order-viruses-are-the-new-antibi
otics?utm_term=.gx9r14KJ3#.ed4QJgEj2 [https://perma.cc/H2SV-LDHZ].
40 Lecia Bushak, A Brief History Of Antibiotic Resistance: How A Medical Miracle Turned
Into The Biggest Public Health Danger Of Our Time, MEDICAL DAILY (Feb. 17, 2016), http://
www.medicaldaily.com/antibiotic-resistance-history-373773 [https://perma.cc/5JGX-7W2J].
41 Ventola, supra note 5, at 277–78.
42 Id. at 280–81.
43 Ananya Mandal, Staphylococcus Aureus and Disease, NEWS-MEDICAL (May 2005),
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resistance to numerous brands of traditional antibiotics, including all of
the penicillin-derived brands.44 Due to this resistance, MRSA is notoriously
difficult to treat in humans, and often able to spread to patients in hospitals
themselves.45 The Centers for Disease Control (“CDC”) estimate that 11,285
people are killed by MRSA annually.46 In the United States, the antibiotic
drug Vancomycin—a non-penicillin-derived antibiotic—is currently used
as a treatment against MRSA.47 But it too is losing its efficacy as strains
of S. aureus are beginning to develop resistance to this drug as well.48
Moreover, MRSA, while possibly the most notable example of
antibiotic resistant bacterial infection, is far from the only such patho-
genic bacteria, and its pattern of evolving ever-increasing resistances is
hardly unique.49 Indeed, new strains of antibiotic-resistant pathogenic
bacteria continue to emerge periodically.50 Recently, for example, a Nevada
woman died from an infection caused by an unusually resilient strain of
Klebsiella pneumoniae which proved to be resistant to 26 different anti-
biotic medicines.51
To deal with such virulent strains of pathogenic bacteria, doctors
have been forced to turn to especially potent antibiotic drugs.52 One of the
most common such drugs is polymyxin E, also known as Colistin.53 How-
ever, Colistin is used only as a drug of last resort because of its highly
negative side effects.54 Although an effective antibiotic, Colistin is also a
http://www.news-medical.net/health/Staphylococcus-Aureus-and-Disease.aspx [http://
perma.cc/9S8J-9PVE].
44 Ventola, supra note 5, at 277–81.
45 Id. at 281.
46 MRSA Fast Facts, CNN (June 9, 2016), http://www.cnn.com/2013/06/28/us/mrsa-fast
-facts/ [http://perma.cc/Z7RG-CP33].
47 Scott Micek, Alternatives to Vancomycin for the Treatment of Methicillin-Resistant
Staphylococcus aureus Infections, 45 CLINICAL INFECTIOUS DISEASES s184 (2007).
48 Id.
49 See Ventola, supra note 5.
50 Huys et al., supra note 12.
51 Sara Zhang, A Woman Was Killed by a Superbug Resistant to All 26 American Antibi-
otics, THE ATLANTIC (Jan. 13, 2017), https://www.theatlantic.com/health/archive /2017/01/a
-superbug-resistant-to-26-antibiotics-killed-a-woman-itll-happen-again/513050/ [http://
perma.cc/X8EY-4CC5].
52 Brent Bambury, An American Woman Just Died From a Superbug Resistant to 26 Dif-
ferent Antibiotics, CBC RADIO (Jan. 20, 2017), http://www.cbc.ca/radio/day6/episode-321
-women-s-march-on-washington-hamilton-s-one-last-time-jerry-maguire-circus-fare wells
-and-more-1.3941806/an-american-woman-just-died-from-a-superbug-resistant -to-26-dif
ferent-antibiotics-1.3941881 [http://perma.cc/WYP6-9E6D].
53 Id.
54 Id.
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powerful nephrotoxin and neurotoxin, which has a tendency to cause severe
kidney and nerve damage, sometimes leading to the failure of these organ
systems.55 Additionally, powerful multipurpose antibiotics such as Colistin
or Vanomycin also pose a risk to beneficial bacteria endemic to the human
body, including those that make up our gut flora.56 This presents serious
health concerns to patients, as culling such symbiotic bacteria would de-
prive these patients of their beneficial effects—such as their aid in the
process of normal digestion.57 In the vacuum left by the symbiotic bacteria’s
absence or diminishment, antibiotic resistant pathogenic bacteria can es-
tablish themselves in the fertile areas of the human body that are normally
inhabited by our bacterial symbiotes, thus giving such pathogens a strong-
hold in the human body from which to grow.58 However, for all the associ-
ated risks, even Colistin is beginning to lose its efficacy against certain
virulent strains of bacteria, as it too was unable to combat the aforemen-
tioned strain of antibiotic resistant K. pneumoniae bacteria.59
Thankfully, research further east has yielded some encouragement.
Researchers at the Eliava Institute are also looking into the treatment
of antibiotic resistant bacteria using bacteriophage medicine, with promis-
ing results.60 Using phage therapy techniques on mice infected with MRSA,
researchers have managed to synthesize a treatment that is 97% effec-
tive in the infected mice.61 This demonstrates one of the main advantages
that phage therapy has over traditional antibiotic medicine: while bacteria
are often able to develop resistance to traditional antibiotics, bacterio-
phages evolve much more quickly than the bacteria they prey upon.62 As
viruses, bacteriophages have short generation times and high mutation
rates, allowing them to evolve quickly to meet new environmental condi-
tions.63 Furthermore, this high rate of evolution has led to the emergence
55 Herbert Spapen et al., Renal and Neurological Side Effects of Colistin in Critically Ill
Patients, 1 ANNALS OF INTENSIVE CARE 14, 14–15 (2011).
56 See Reardon, supra note 8.
57 Maryn McKenna, Antibiotics: Killing Off Beneficial Bacteria . . . for Good?, WIRED
(Aug. 26, 2011), https://www.wired.com/2011/08/killing-beneficial-bacteria/ [https://perma
.cc/VG4Q-YGZ8].
58 Id.
59 Bambury, supra note 52.
60 Zuzanna KaŸmierczak et al., Facing Antibiotic Resistance: Staphylococcus aureus Phages
as a Medical Tool, 6(7) VIRUSES 2551, 2559 (2014).
61 Id. at 2555.
62 Carol Potera, Phage Renaissance: New Hope against Antibiotic Resistance, 121(2) EN-
VIRONMENTAL HEALTH PERSPECTIVES A49–50 (2013).
63 KEITH LEPPARD ET AL., THE EVOLUTION OF VIRUSES, INTRODUCTION TO MODERN VIROLOGY
272–73 (2007).
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of innumerable strains of bacteriophages.64 Indeed, scientists estimate
that “[a] pinch of soil or drop of seawater, for example, contains many mil-
lions of bacteriophages” and that “[p]hages are probably the most diverse
things on the planet.”65 Some researchers even speculate that bacterio-
phages outnumber all other organisms put together.66 Thus, it is unlikely
that bacteria could develop any natural resistance to bacteriophage medi-
cines, as they are able to with conventional antibiotics.67
In addition, bacteriophage species tend to be highly specialized,
preying exclusively upon one strain or species of bacteria.68 This means
that bacteriophages pose little to no threat to the beneficial bacteria within
the human body, unlike many conventional antibiotic drugs—especially
very potent drugs such as Colistin and Vanomycin.69
III. CONCERNS WITH PHAGE THERAPY
For all of its potential benefits, some scientists have apprehen-
sions about the use of phage therapy. Notably, there is scientific concern
with the use of lysogenic (also known as temperate) bacteriophages in
phage therapy.70 This particular group of bacteriophages is able to alter
the genetic material of a host bacterium without destroying it.71 This
ability means lysogenic bacteriophages have the potential to actually turn
nonpathogenic, benign bacteria species into pathogenic, harmful bacte-
ria.72 The risks associated with the creation of a new disease-causing
bacteria are potentially severe.73 Though it is difficult to say with cer-
tainty how a new species or strain of bacteria would behave, there is every
64 Reardon, supra note 8.
65 John Travis, All the World’s a Phage: Viruses That Eat Bacteria Abound—and Surprise,
SCIENCE NEWS (July 12, 2003), http://www.phschool.com/science/science_news/articles/all
_worlds_phage.html [http://perma.cc/8UTF-MB8U].
66 Id.
67 Id.
68 Reardon, supra note 8.
69 Id.
70 Duckworth & Gulig, supra note 4, at 61.
71 Xavier Wittebole et al., A historical overview of bacteriophage therapy as an alternative
to antibiotics for the treatment of bacterial pathogens, 5(1) VIRULENCE 226 (2013); see also
Harald Brüssow et al., Phages and the Evolution of Bacterial Pathogens: from Genomic
Rearrangements to Lysogenic Conversion, 68(3) MICROBIOLOGY AND MOLECULAR BIOLOGY
REVIEW 560, 574–75 (2004).
72 Duckworth & Gulig, supra note 4, at 61.
73 See id.
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possibility that such new bacteria could be highly virile and deadly.74 In
addition to spreading genes that make previously benign bacteria patho-
genic, lysogenic bacteriophages could actually spread genes that increase
microbial resistance to antibiotic medicine.75 For this reason, lysogenic
bacteriophages are typically not used for phage therapy.76 To avoid this
risk entirely, the use of lysogenic bacteriophages in bacteriophage medi-
cines could be banned outright by appropriate regulatory organizations
without greatly hindering the development of bacteriophage medicines
using non-lysogenic (lytic) bacteriophages.77
Lytic bacteriophages also pose potential risks to human health,
albeit less severe than those posed by lysogenic bacteriophages.78 Lytic
bacteriophages can cause patients harm by exposing them to bacterial
endotoxins.79 Certain pathogenic bacteria contain substances that are
toxic to humans within their cell walls, collectively known as endotoxins.80
When lytic viruses break open (or, lyse) infected bacteria during normal
viral reproduction, these endotoxins can be released.81 If many of these
endotoxin-containing bacteria are broken open within the human body,
these toxins have the potential to cause symptoms ranging from very
minor82 to potentially life-threatening.83 However, this reaction, known
as the Herxheimer reaction, is not unique to phage therapy.84 It has been
observed to happen in the course of conventional antibiotic treatment,
which also destroys bacteria cells and releases their endotoxins.85
The scientific community has also raised concerns that bacterio-
phages may trigger an immune response in patients which could prove
harmful to the body.86 Though bacteriophages pose no threat to our own
74 Id.
75 Wittebole et al., supra note 71, at 228.
76 Duckworth & Gulig, supra note 4, at 61.
77 Wittebole et al., supra note 71, at 228.
78 Maheshwar Mathur et al., Bacteriophage Therapy: An Alternative to Conventional
Antibiotics, 51 J. OF THE ASS’N OF PHYSICIANS OF INDIA 593, 594 (2003).
79 Id.
80 Ernst Rietschel et al., Bacterial Endotoxin: Molecular Relationships of Structure to
Activity and Function, 8(2) FASEB J. 217 (1994).
81 Id.
82 The Herxheimer Reaction—Feeling Worse Before Feeling Better, SILVER COLLOIDS (2012),
http://www.silver-colloids.com/Pubs/herxheimer.html [http://perma.cc/L3KJ-HKJC].
83 Mathur et al., supra note 78, at 594.
84 James Hurley, Antibiotic-Induced Release of Endotoxin: A Therapeutic Paradox, 12(3)
DRUG SAFETY 183 (1995).
85 Id.
86 Catherine Loc-Carrillo & Stephen Abedon, Pros and Cons of Phage Therapy, 1(2) BAC-
TERIOPHAGE 111, 112 (2011).
2018] MICROSCOPIC ALLIES 683
cells, the body’s immune system nonetheless recognizes them simply as
viruses, and will naturally seek to destroy or expel them from the body.87
Though the immune system is designed to protect the body from patho-
gens, not all immune reactions are beneficial to the body.88 Indeed, some
are actually harmful.89 An allergic reaction, for instance, is one common
type of immune reaction which can cause various levels of discomfort or
even serious harm to the body, sometimes even resulting in death.90
However, bacteriophage researchers have not noticed any seriously harm-
ful immune reactions to bacteriophage medicines as of yet.91 Rather, what
has been observed is that a human immune system that has already
been triggered by bacterial illnesses will also strike out at bacteriophages
in the body, which can inhibit the efficacy of phage therapy in clinically
significant ways.92 Nonetheless, with more research it may be possible for
clinicians to account for impediments to phage therapy caused by the
immune system.93 Additionally, even if phage therapy did lead to severe
immune reactions in some cases, it would hardly be unique among
medicines.94 Many people worldwide suffer from allergic reactions to
traditional antibiotics, which can cause symptoms ranging from uncom-
fortable rashes and blisters to life-threatening toxic epidermal necrolysis
and anaphylaxis.95
In addition, phage therapy may be mistrusted by the wider public
for its use of viruses, which could potentially prove fatal to the develop-
ment of bacteriophage medicines.96 Though bacteriophages do not prey
on eukaryotic—or nonbacterial—cells, and thus do not pose a threat of
attacking human cells and causing viral infection of humans, these details
may be lost on certain members of the public.97 In the words of Mzia
Kutateladze, head of the scientific council of the Eliava Institute, “this is
87 Katarzyna Hodyra-Stefaniak et al., Mammalian Host-Versus-Phage immune response
determines phage fate in vivo, 5 SCI. REP. 14802 at 7 (2015).
88 See Ian Kimber & Rebecca Dearman, Immune Responses: Adverse Versus Non-Adverse
Effects, 30 TOXICOLOGIC PATHOLOGY 54, 56–57 (2002).
89 Id. at 54.
90 Id. at 56.
91 Loc-Carrillo & Abedon, supra note 86, at 112.
92 Hodyra-Stefaniak et al., supra note 87, at 8.
93 See id.
94 Antonio Romano & Jean-Christoph Caubet, Antibiotic Allergies in Children and Adults:
From Clinical Symptoms to Skin Testing Diagnosis, 2 J. OF ALLERGY AND CLINICAL
IMMUNOLOGY: IN PRACTICE 3, 4, 8 (2014).
95 Id. at 3–4, 7–9.
96 See Reardon, supra note 8.
97 Id.
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a virus, and people are afraid of viruses.”98 While any public concerns about
the risk of bacteriophages causing viral diseases would be scientifically
unfounded, a public outcry against the use of phage therapy nonetheless
has the potential to impede or even block its adoption.99 Such patterns of
powerful public outcry without substantial scientific backing are not new
to medical science.100 Indeed, one need look no further than the “anti-
vaxxer” movement to see the repercussions that even a vocal minority can
have on public policy, and the influence that such a minority can wield
over policymakers.101 Thankfully, there has not yet been any such outcry,
as the public largely doesn’t know about phage therapy.102 It is possible that
with adequate attempts to educate the public about the actual risks and
benefits associated with phage therapy, unfavorable misapprehensions
about it could be dispelled, and this obstacle to the implementation of
phage therapy could be preempted.103
IV. CURRENT REGULATORY SITUATION
A. Federal Regulations
In the past decade or so, appropriate United States federal regula-
tory agencies, namely the FDA and the USDA have approved the use of
several bacteriophage products for commercial use. For instance, in 2006,
the FDA awarded a generally recognized-as-safe (“GRAS”) status to the
Micreos product LISTEX, a bacteriophage coating for cheese which kills
the bacteria Listeria monocytogenes.104 The USDA, meanwhile, has funded
research into bacteriophage products and medicines which could combat
bacterial infections of plants or livestock.105 This research includes one
ambitious project aimed at completely replacing the typical cocktail of
antibiotics regularly given to farm animals in order to help them ward
off infections—a practice which the USDA is concerned may lead to the
advent of antibiotic-resistant pathogens which would pose a health risk
98 Id.
99 Loc-Carrillo & Abedon, supra note 86, at 113.
100 Peter Hotez, How the Anti-Vaxxers Are Winning, N.Y. TIMES (Feb. 8, 2017), https://
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to livestock and humans alike—with bacteriophage medicines, effectively
creating a veterinary application of phage therapy.106
However, despite this movement toward the greater acceptance
of bacteriophage products, the FDA has yet to approve phage therapy for
medicinal use in humans.107 In large part, this is because the FDA requires
that antibiotic drugs be tested for efficacy and safety individually, and
classes bacteriophage medicines as antibiotic drugs.108 This individual
efficacy testing is intended for conventional antibiotic drugs, which are
designed to be effective against a wide array of bacteria species and
strains.109 Thus, under the current FDA regulations, different species of
bacteriophages would be considered individual antibiotic drugs, and as
such would need to be individually approved.110
However, this model is a poor fit for phage therapy. Unlike con-
ventional antibiotics, which are able to kill a diverse array of pathogens,
bacteriophages prey on specific types of bacteria.111 As a result, phage
therapy techniques often feature “multi-phage cocktails,” which include
numerous species of bacteriophages, to maximize the treatment’s efficacy
when the exact species or strain of bacteria infecting the patient is not
known.112 Indeed, researchers at the Eliava Institute have admitted that
the bacteriophage injections they administer to patients are often so mixed
that they do not know the exact combination of phage species that make
up the cocktail.113 While phage cocktails would be able to meet FDA
efficacy standards, individual phages would not.114
Outside of the antibiotic context, however, the FDA has approved
drug cocktails collectively rather than their individual component drugs.115
For example, the FDA regularly approves FluMist®—a yearly live-virus
influenza vaccine containing three or four attenuated flu viruses—as a
whole rather than approving each individual virus.116
Furthermore, recent Supreme Court cases—Mayo Collaborative
Services v. Prometheus Laboratories, Inc., and Association for Molecular
106 Id.
107 Cooper et al., supra note 9, at 1.
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Pathology v. Myriad Genetics, Inc.—have left the patentability of bacterio-
phage products ambiguous.117 First, pursuant to Prometheus, the applica-
tion of a natural phenomenon or “law of nature,” even if just discovered,
cannot be patented if it lacks an “inventive concept.”118 An invention’s
“inventive concept” must ensure that the patent acts as more than a
monopoly on the use of the natural law itself.119 The Court further elabo-
rated that “conventional or obvious pre-solution activity” is not necessarily
sufficient to add such an element of inventiveness.120 Second, the Court
in Myriad—applying Prometheus—ruled that would-be inventors cannot
claim patent protection on naturally occurring DNA patterns, because the
act of discovering or isolating genetic material is not the same as inventing
it.121 Rather, inventors can only receive patent protection for synthetically
created genetic patterns, such as composite DNA (“cDNA”).122 Some schol-
ars contend that, because bacteriophages are natural phenomena possess-
ing and distinguished by their naturally occurring genetic material, these
cases leave the patent-eligibility of bacteriophage products ambiguous.123
Such federal regulatory hurdles present serious obstacles to the
development and exploitation of bacteriophage medicines. As a matter of
economics, pharmaceutical companies—who fund the lion’s share of re-
search and development of new drugs124—are unlikely to invest in devel-
oping products which will not yield short-term or medium-term profits.125
Because an unapproved drug would see very little use, and because the
uncertainty surrounding the patentability of bacteriophage products af-
fords them little certainty that their intellectual property will be protected,
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pharmaceutical companies are unlikely to invest in developing bacterio-
phage medicines under the current scheme.126 Thus, for phage therapy
to become a reality in American medicine, the FDA must make regulatory
accommodations for phage therapy.
B. State-Level Developments
Despite the stagnation at the federal level, three states thus far
have legalized the medical use of phage therapy: Texas, Oregon, and
Washington.127 From these states, two distinct models can be observed.
Each model implies a distinct attitude toward the medical use of bacte-
riophages, with implications and consequences that must be carefully
considered going forward.
1. The Washington-Oregon Model
The sister states of Washington and Oregon both allow for the medi-
cal use of phage therapy within their borders.128 These two states utilize
a sufficiently similar model governing the use of bacteriophage medicines,
among other experimental products, that we can class them together.129
In these states, phage therapy is one of many unconventional remedies
which may be prescribed by naturopathic physicians.130 Naturopathic
physicians, or naturopaths, are practitioners who make use of naturo-
pathic medicines.131 Naturopathic medicine is defined under Washington
law as “vitamins; minerals; botanical medicines; homeopathic medicines;
hormones; and those legend drugs and controlled substances consistent
with naturopathic medical practice in accordance with rules established
by the [state naturopathic] board,”132 and under Oregon law as “the disci-
pline that includes physiotherapy, natural healing processes and minor
surgery and has as its objective the maintaining of the body in, or of re-
storing it to, a state of normal health.”133 Naturopaths in Washington and
Oregon have the legal authority to prescribe the use of medicines used
126 Fischetti et al., supra note 11, at 1509.
127 Faltys, supra note 10; KUCHMENT, supra note 10, at 115–18.
128 Faltys, supra note 10.
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extensively in other countries.134 Certain medical doctors, such as Dr. Betty
Kutter, who heads the Evergreen Phage Lab at Evergreen State College
in Olympia, Washington, have taken advantage of these laws in order to
research and use bacteriophage medicines on patients.135
However, this treatment betrays an attitude toward phage therapy
rife with troublesome implications. Naturopathic medicine is ill-regarded
by scientific and medical professionals, many of whom regard it as pseudo-
scientific.136 Naturopathy’s poor reputation is reflected in law. The FDA
takes a dim view of naturopathy, and has at times considered curbing its
practice.137 Furthermore, two states, South Carolina and Tennessee, have
even outright banned the practice of naturopathy within their borders.138
By placing the development and use of phage therapy within the purview
of naturopaths, the Washington-Oregon Model implicitly associates phage
therapy with pseudoscientific remedies, despite the former’s long history
and scientific merit.
Additionally, naturopathic physicians’ scientific, medical, and tech-
nical education often falls far short of what would be expected of conven-
tional medical professionals, even in states where they are officially
licensed.139 Thus, Washington and Oregon place phage therapy in the
hands of individuals who are likely incapable of effectively researching
and utilizing bacteriophage medicine.140
2. The Texas Model
Like Washington and Oregon, the state of Texas also allows for
research into and use of bacteriophages.141 However, unlike Washington
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and Oregon, Texas does not put phage therapy in the purview of naturo-
paths.142 Rather, Texas places phage therapy in the hands of licensed medi-
cal practitioners by allowing doctors to prescribe bacteriophage medicine
as a supplement to, but not in lieu of, established medical techniques.143
Under this model, Texas fosters a complementary relationship
between bacteriophage medicine and conventional antibiotic medicine,
which allows each to offset the weaknesses of the other—thus improving
the efficacy of both. It allows physicians to test new bacteriophage medi-
cines without putting their patients at risk by subjecting them to an
experimental remedy, as the conventional antibiotic medicine provides
an anchor. Certain antibiotics have even been observed to promote phage
virulence.144 At the same time, this dual method helps to reduce the risks
associated with conventional antibiotic medicine, such as the emergence
of antibiotic-resistant strains of pathogenic bacteria, because bacterio-
phages effectively eliminate bacteria remaining after antibiotic treat-
ment.145 In this way, bacteriophages actually enhance the effectiveness
of conventional antibiotics.146 Indeed, some research suggests that using
both methods together is actually more effective at killing pathogens
than using either method in isolation.147
V. ARGUMENT
In an era in which once tractable pathogenic bacteria are developing
resistance to our strongest conventional antibiotic medicines at alarming
rates,148 the development of new, efficacious medicines capable of control-
ling virulent bacterial pathogens is crucial. Because phage therapy is one
of the most promising new alternatives to conventional antibiotic medi-
cine,149 our society should prioritize its development and full exploitation.
Reforming federal regulatory policies on phage therapy is neces-
sary to induce the maximal exploitation of phage therapy.150 As discussed
above, pharmaceutical companies are unlikely to invest money to research
142 KUCHMENT, supra note 10, at 115–18.
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and develop a medicine which is unlikely to be approved under the FDA’s
current policies.151 Thus, compelling the FDA to provide regulatory accom-
modation for phage therapy must be a goal and priority for the advocate
of regularizing phage therapy. It may not even require great creativity to
imagine what form regulatory accommodation for phage therapy would
take. Indeed, if the FDA were to distinguish bacteriophage medicines from
conventional antibiotics, allowing them to approve phage cocktails as a
whole—similar to how the FDA treats FluMist®—bacteriophage medi-
cines would meet FDA safety and efficacy requirements.152 What may prove
more difficult is impelling the FDA to change its policy on phage therapy
so dramatically. To that end, legalizing phage therapy at the state level
may prove useful.
Although state regulations are not sufficient in themselves to
significantly spread or regularize the use of bacteriophage medicine,
individual states can help to speed the federal regulatory adoption of and
accommodation for phage therapy. By crafting legislation or regulatory
policies which allow for the research and use of bacteriophage medicine
within their own territory, research and treatment centers will be able
to spread across the country, just as they have in Texas and Washing-
ton.153 Through these research centers, members of the medical establish-
ment, as well as the general population, will gain more exposure to the
concept and practice of phage therapy, allowing it to enter the cultural
and scientific conscience of the American people. In the event that the
American people and wider medical establishment become familiar with
and accepting of phage therapy, the FDA will have no choice but to respond
to these cultural developments by making regulatory accommodations for
phage therapy.
However, there are pitfalls which states would do well to avoid
when accommodating the development and use of phage therapy. Namely,
states should not put the onus for developing and using phage therapy
on naturopathic physicians, as is the practice in Washington and Oregon.154
Naturopathy is considered disreputable pseudoscience by most of the
scientific and medical community, and the scientific, medical, and technical
education of even state-licensed naturopaths most often falls far short of
what would be expected of conventional medical professionals.155 Therefore,
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by putting the development and use of phage therapy in the purview of
naturopaths, states would be placing the onus for the research and de-
velopment of bacteriophage medicines on people who often lack the requi-
site knowledge or temperament to do so while also associating phage
therapy with ostensibly pseudoscientific naturopathic remedies.156
The latter point is especially salient when trying to influence
federal regulatory policy by raising professional and cultural awareness
of phage therapy. Placing phage therapy in the purview of naturopaths
risks causing many scientists, researchers, and physicians to view phage
therapy as a pseudoscience, in the same vein as other naturopathic reme-
dies, rather than as a legitimate medical technique. By causing medical
professionals to associate phage therapy with pseudoscience, or even to
view it as pseudoscience, states placing phage therapy in the purview of
naturopaths could actually hamper any effort to impel the FDA to recog-
nize the legitimate medical value of phage therapy, let alone to make
regulatory accommodations for it.
In contrast, the Texas model provides a good alternative to the
flawed Washington-Oregon model. Rather than placing phage therapy in
the purview of naturopaths, the Texas model puts licensed medical prac-
titioners in charge of developing and administering bacteriophage medi-
cines.157 Because licensed physicians are at the helm of the development
and administration of phage therapy under the Texas model, the legiti-
macy of phage therapy will not suffer from association with pseudoscience,
as it does under the Washington-Oregon model. Furthermore, because
medical doctors are generally better medically, scientifically, and techni-
cally educated than even state-licensed naturopaths,158 having medical
doctors in command of the research and development of bacteriophage
medicine will yield more fertile results than those that would be pro-
duced under the Washington-Oregon model.
The Texas model is also desirable for the complementary relation-
ship that it builds between phage therapy and traditional antibiotic
techniques. With bacteriophage medicine used as a complement to, but
not in lieu of, established medical techniques, these two treatments are
able not only to improve upon the other’s weaknesses but also—according
to some studies—kill pathogens more effectively than either method used
in isolation.159 This complementary relationship would also help lead to
156 See supra Section IV.B.1.
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greater societal understanding of phage therapy. It both provides a viable
look at how phage therapy could be used after cultural and regulatory
acceptance, and also allows both medical professionals and society at
large to get accustomed to seeing this combination of methods for fighting
bacterial infection.
CONCLUSION
In order to effectively advocate for the use of phage therapy in the
United States, we must first take stock of the resources at our disposal.
Ultimately, change must happen at the federal level—namely, to the FDA’s
policy toward phage therapy—before serious headway can be made on
developing effective and reliable bacteriophage remedies to bacterial
infections.160 However, the importance of state law should not be over-
looked. State law is an important and relatively accessible way to influ-
ence public perception and opinion. As such, even though it alone will not
be sufficient to precipitate the spread of bacteriophage medicine to every
corner of the nation, it can build public opinion from the ground up, and
lend momentum to the cause of normalizing phage therapy. Thus, advo-
cates for the use of phage therapy should promote both the revision of
relevant FDA regulation and the legalization of phage therapy at the
state level. However, it is imperative for states to legislate in a careful
and deliberate way, ever cognizant of the assumptions, implications, and
consequences ingrained in the laws they create.
As humanity’s understanding of the microenvironment increases,
nations around the world will need to come to terms with their relation-
ship with the denizens of that microscopic world—in law, science, and
medicine alike. This relationship is complex and mutually influential;
human actions play a very significant role in shaping and maintaining
a healthy microenvironment, which then can impact our health and
quality of life in drastic and marked ways. Key to shaping a healthy
microenvironment will be developing sound policy respecting our already
symbiotic relationship with the most populous and diverse denizens of
the microscopic world: the humble bacteriophages. By maintaining a
symbiotic relationship with bacteriophages, humanity stands to create
a microenvironment hospitable to human life, and conducive to human
flourishment. Phage therapy is but one example of the exciting and
potentially revolutionary technologies that can result from such a con-
certed effort.
160 Keen, supra note 108, at 238–39.
